Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Accumulated Expenses (2021 - 2025)

Valion Bio has reported Accumulated Expenses over the past 5 years, most recently at $194000.0 for Q2 2025.

  • For Q2 2025, Accumulated Expenses rose 177.14% year-over-year to $194000.0; the TTM value through Jun 2025 reached $194000.0, up 177.14%, while the annual FY2023 figure was $218000.0, 50.34% up from the prior year.
  • Accumulated Expenses for Q2 2025 was $194000.0 at Valion Bio, up from $40000.0 in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $218000.0 in Q4 2023 and troughed at $40000.0 in Q3 2024.
  • A 5-year average of $139000.0 and a median of $145000.0 in 2022 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: decreased 29.61% in 2022 and later skyrocketed 177.14% in 2025.
  • Year by year, Accumulated Expenses stood at $206000.0 in 2021, then decreased by 29.61% to $145000.0 in 2022, then skyrocketed by 50.34% to $218000.0 in 2023, then plummeted by 81.65% to $40000.0 in 2024, then skyrocketed by 385.0% to $194000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for TIVC at $194000.0 in Q2 2025, $40000.0 in Q3 2024, and $70000.0 in Q2 2024.